FHTX
Foghorn Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.87
+1.08%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.84
From 52W high−73.55%
Volume440806.00
Market cap$111.05M
P/E (TTM)—
P/S (TTM)3.0x
Div yield—
Key dataOct 19, 2026
Open
$1.84
From 52W high
−73.55%
Volume
440806.00
Market cap
$111.05M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
17.0
MomentumView details →
1D Return
+1.08%
YTD Return
−65.46%
SummaryUpdated Jun 1, 2026
Foghorn Therapeutics Inc. (NASDAQ:FHTX) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in Cambridge, Massachusetts. The company went public in October 2020 and focuses on discovering and developing innovative cancer treatments by targeting the chromatin regulatory system, a fundamental cellular mechanism that controls gene expression. Foghorn has built its drug discovery efforts around a proprietary platform called Gene Traffic Control, which identifies vulnerabilities in cancer cells that can be exploited with targeted therapies.
Similar companies
Latest newsMore news →
Foghorn Therapeutics and Eli Lilly dissolved their cancer-drug partnership and plan no future collaborations.19d agoFoghorn Therapeutics and Eli Lilly decided not to advance the FHD-909 program and the selective SMARCA2 degrader program, and Foghorn will cut about 40% of its workforce while prioritizing its wholly owned pipeline, extending its cash runway into the second half of 2029.19d agoFoghorn Therapeutics Inc. reported its Q2 2026 financial results, with collaboration revenue of $16.1 million, a net loss of $7.2 million, and diluted EPS of -$0.10.75d ago